Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AgelessRx vs NovoCare Pharmacy

By GLP-1 ScorecardUpdated

AgelessRx
Site position #17

Higher grade

NovoCare Pharmacy
Site position #491

Lower grade

Score comparison

AgelessRx has the higher recorded score — 84.3/100 to 55.2/100.

AgelessRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Conventional and microdose GLP-1 programs with continuing care; branded prescriptions involve a separate pharmacy payment.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueAgelessRx +66
90
24
Dose & formulationAgelessRx +14
80
66
Clinical oversightAgelessRx +9
83
74
Labs & monitoringAgelessRx +31
82
51
FulfillmentAgelessRx +8
84
76
Contract termsAgelessRx +30
85
55
AgelessRx · top barNovoCare Pharmacy · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricAgelessRxNovoCare Pharmacy
WeighScore84.3/10055.2/100
GradeBC
Site position#17#491
SemaglutideNot verified (current medication-specific quote required)Branded Wegovy injection: $349 standard fill (4 pens / 28 days); starter, HD and tablet offers vary by dose and eligibility.
TirzepatideMicrodose: $109 first month, then $318 every 2 months ($159/mo); full-dose quote requiredNot disclosed
CoverageAdvertises US service; confirm treatment-specific state availabilityBlinkRx network pharmacies collectively cover 50 states, DC and Puerto Rico; confirm the assigned dispenser and eligibility.
Brand-name accessYesYes
Oral / sublingualYesYes
AgelessRx

Site position #17 · B

Strengths

  • Conventional and lower-dose GLP-1 programs advertised
  • Wegovy pens and oral-tablet consultations advertised
  • Continuing messaging and check-ins advertised

What to consider

  • Conventional medication-specific monthly quotes not verified
  • Microdose introduction renews as a two-month charge
  • Branded medication has a separate pharmacy bill
  • Treatment-specific state eligibility and assigned dispenser need confirmation
NovoCare Pharmacy

Site position #491 · C

Strengths

  • Names BlinkRx and legacy pharmacy arrangements rather than leaving the fulfillment route anonymous.
  • Publishes a two-fill $199 Wegovy injection starter offer with specific eligibility and prescription/shipping deadlines.
  • Publishes dose-specific Wegovy tablet and injection self-pay offers for comparison.
  • Advertises free home delivery powered by BlinkRx.
  • Provides independent prescriber options as well as delivery and pharmacy-pickup information.

What to consider

  • Reviewed offers cover branded semaglutide products, including Wegovy and Ozempic; no tirzepatide or compounded offer was established.
  • A prescription is required; linked independent care does not establish included visits or follow-up.
  • The medication offer does not establish an included prescriber follow-up plan or a complete selected-order refund agreement.
  • Manufacturer-set pricing can change at any time
  • Eligible Wegovy injection starter pricing covers two 28-day fills under the delivery offer’s December 31, 2026 prescription and January 31, 2027 shipping deadlines; standard pricing follows.

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard